Investing.com -- Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 3.5% after the company announced positive interim data from its Phase 1/2 clinical study of MRT-2359 in combination with enzalutamide for treating metastatic castration-resistant prostate cancer (mCRPC).
The clinical-stage biotechnology company reported a 100% PSA response rate and 100% disease control rate in patients with androgen receptor (AR) mutations. Among the four patients with AR mutations, two showed RECIST partial responses while two maintained stable disease. The overall disease control rate across all 14 evaluable patients was 64%.
Monte Rosa’s MRT-2359, an orally bioavailable molecular glue degrader targeting GSPT1, demonstrated a favorable safety profile when combined with enzalutamide. Patients primarily experienced mild to moderate gastrointestinal adverse events (Grade 1-2).
"We continue to be highly encouraged by the clinical activity observed with MRT-2359 in combination with enzalutamide in heavily pretreated mCRPC patients, a population with limited therapeutic options," said Markus Warmuth, CEO of Monte Rosa Therapeutics.
The study population included 20 heavily pretreated individuals with advanced CRPC, with 75% previously treated with a second-generation AR inhibitor, 80% with taxane chemotherapy, and 55% with Pluvicto.
Based on these results, Monte Rosa plans to initiate a new signal-confirming Phase 2 study in 2026, evaluating MRT-2359 in combination with a second-generation AR inhibitor in mCRPC patients with AR mutations. The company expects to present updated data at the ASCO Genitourinary Cancers Symposium in February 2026.
The company also announced plans to present interim Phase 1 data on MRT-8102, its NEK7-directed molecular glue degrader for inflammatory diseases, in early 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.








